Your SlideShare is downloading. ×
Bayer HealthCare Overview March 2011
Content Overview Group Structures   Pharma  Research & Development   Consumer Health   Financial Data   People and Respons...
Full year sales:  €  16.9 billion 55,700 employees R&D expenditures:  €  2.1 billion As of December 31, 2010
Group Structure Currenta Bayer Business Services Bayer HealthCare Bayer MaterialScience Bayer CropScience Business areas S...
Business Areas High-tech materials Health care Nutrition MaterialScience HealthCare CropScience
Bayer HealthCare Divisions Animal Health Medical Care Consumer  Care Pharmaceuticals Pharma Consumer Health
Bayer HealthCare Divisions Consumer Care <ul><li>Non-prescription drugs </li></ul><ul><li>Vitamins </li></ul>Pharmaceutica...
Bayer HealthCare Divisional Headquarters Europe Africa   /   Middle East North America Asia   /   Pacific Latin   America ...
Bayer HealthCare Full Year 2010 Employees* 55,700 Sales   €  16,913 million EBITDA before special items €  4,405 million C...
Global Leader in Specialty Pharmaceuticals and Consumer Health Animal Health Division 64.5% 6.6% 19.9% €   16,913 million ...
Bayer HealthCare Aspirations <ul><li>Be one of the world’s leading diversified healthcare companies </li></ul><ul><li>Stre...
Employees in 2010 R&D  7,700 Bayer HealthCare 55,700 Employees in full-time equivalents Pharmaceuticals 38,000 Consumer He...
Bayer HealthCare Pharmaceuticals
Bayer HealthCare Pharmaceuticals Key Data <ul><li>Biggest pharma company in Germany </li></ul><ul><li>focus on 2 major bus...
Bayer HealthCare Pharmaceuticals  Women’s Healthcare <ul><ul><li>We are the world’s leading company in the field of hormon...
Bayer HealthCare Pharmaceuticals General Medicine <ul><ul><li>We are strong partners in the areas of infectious diseases a...
Bayer HealthCare Pharmaceuticals Specialty Medicine <ul><ul><li>We are among the world’s leading companies in the fight ag...
Bayer HealthCare Pharmaceuticals Diagnostic Imaging <ul><ul><li>We are the global leader in contrast media </li></ul></ul>...
Research & Development
Probability of success from research to market approval: <1% Drug research  Preclinical Clinical trials Evaluation/ Approv...
Bayer HealthCare Pharmaceuticals   Research Areas <ul><li>Pulmonary hypertension   /   heart failure </li></ul><ul><li>Thr...
Bayer HealthCare Pharmaceuticals  Research at a Glance Berkeley / San Francisco <ul><li>Hematology  </li></ul><ul><li>Biol...
Our R&D Pipeline Provides a Balanced Mix of NME and LCM Opportunities New Molecular Entities (NME) Life Cycle Management  ...
Improving R&D Efficiency and Maximizing the Value of Transformational Late-Stage Pharmaceutical Pipeline Assets <ul><li>Es...
Consumer Health
Consumer Health Key Data Sales in  €  million 977 1,120 Animal Health <ul><li>Food Animal Products </li></ul><ul><li>Compa...
Leading Growth in Consumer Health at Bayer HealthCare Animal Health <ul><li>Continue growth at or above market at high pro...
Consumer Health Top 10 Products 2009 2010 Contour ®   (Medical Care)   601 602 Aspirin ®  *  (Consumer Care)   400 418 Adv...
Consumer Health Animal Health <ul><ul><li>Animal Health is a top player with benchmark profitability which supplies soluti...
Consumer Health Consumer Care <ul><ul><li>Consumer Care is a top-tier OTC (over the counter) player </li></ul></ul><ul><ul...
Consumer Health Medical Care <ul><ul><li>With Diabetes Care, Medical Care is one of the world’s market leaders in the fiel...
Financial Data
Key Data 2010 Bayer HealthCare Sales Pharmaceuticals Consumer Health EBITDA Special items EBITDA before special items EBIT...
Key Data 2010 Pharmaceuticals 2009 2010 Sales Women’s Healthcare and General Medicine Specialty Medicine EBITDA Special it...
Key Data 2010 Consumer Health 2009 2010 Sales Consumer Care Medical Care  Animal Health EBITDA Special items EBITDA before...
People and Responsibility
Our Vision  Science For A Better Life As an innovative healthcare company, we will: <ul><li>Shape the future with innovati...
Our Values <ul><li>Leadership </li></ul><ul><li>Be passionate for people and performance </li></ul><ul><li>Show personal d...
Responsible Action in Society As a research-based pharmaceutical company, we support projects aimed at reducing the differ...
Sustainable Development and  Corporate Social Responsibility Foundations: <ul><li>Bayer Science & Education Foundation:  S...
The Bayer Sustainability Concept Goal: Successful and sustainable business in harmony  with social objectives and needs Co...
Thank you!
 
Forward-Looking Statements  <ul><li>This presentation may contain forward-looking statements based on current assumptions ...
Upcoming SlideShare
Loading in...5
×

Bayer HealthCare Overview

8,509

Published on

Published in: Health & Medicine, Business
0 Comments
4 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
8,509
On Slideshare
0
From Embeds
0
Number of Embeds
5
Actions
Shares
0
Downloads
0
Comments
0
Likes
4
Embeds 0
No embeds

No notes for slide
  • Left: Bayer researcher Dr. Johannes-Peter Stasch (left) and Professor Hossein Ardeschir Ghofrani from Giessen University Hospital work with a model of a lung. Middle: Vivian Oliver (left) and Gary Henniger from Bayer CropScience examine cotton plants at the new U.S. research center in Lubbock, Texas. Right: Cally Lim (left) inspects wafer-thin solar cells while Wilfredo Aguilar (right) examine luminescent functional films at Bayer’s Singapore facility.
  • Group Companies The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. It has a management holding company structure comprising the holding company, three operating subgroups and three service companies. Bayer offers a wide range of products, including Aspirin ® – probably the world’s best-known pain-reliever, numerous crop protection products, and plastics such as Makrolon ® for CDs, DVDs and automotive glazing. Employees On December 31, 2010, the Bayer Group had 111,400 employees (in full-time equivalents). Sales Group sales in the full year of 2010 came to EUR 35.1 billion (full year 2009: EUR 31.2 billion). Subsidiaries Bayer has 291 subsidiaries throughout the world. Research and Development Research and development expenditures in 2010 added up to EUR 3.1 billion.
  • Group Structure The holding company structure comprises a management holding company, the operating subgroups Bayer HealthCare, Bayer CropScience and Bayer MaterialScience, and the service companies Bayer Business Services, Bayer Technology Services and Currenta. Group Management Board Bayer AG serves as a management holding company. The responsibilities of the Bayer AG Board of Management (Group Management Board) include overall Group strategy, Group portfolio management, fundamental personnel decisions, the allocation of resources for capital expenditures and the overall financial management of the Bayer Group. Corporate Center Support functions for the Group Management Board and the Bayer Group as a whole are provided by the employees of the Corporate Center, which comprises the following departments: Corporate Office; Communications; Investor Relations; Corporate Auditing; Corporate Human Resources &amp; Organization; Finance; Corporate Development; Law &amp; Patents, Insurance; Environment &amp; Sustainability; Group Accounting &amp; Controlling; and Regional Coordination. Further information: http://holding.bayer-ag.com/db/uk/holdingportal.nsf/id/HOME_EN Business areas The business area companies Bayer HealthCare, Bayer CropScience and Bayer MaterialScience are legally independent corporations, each having global responsibility for its business activities. Service companies The service companies Bayer Business Services, Bayer Technology Services and Currenta, which are also legally independent, support the Group companies with their specialist expertise.
  • Bayer’s Strategy for the Future Bayer’s focus for the future is on innovation and growth in the three areas of health care, nutrition and high-tech materials. Bayer’s business is combined in three subgroups that operate virtually independently and are fully aligned to their respective markets. Each subgroup makes an important contribution to solving the challenges facing society. Bayer HealthCare Bayer HealthCare is among the world’s foremost innovators in the field of pharmaceutical and medical products. This subgroup’s mission is to research, develop, manufacture and market innovative products that improve the health of people and animals throughout the world. Bayer CropScience Bayer CropScience, with its highly effective products, pioneering innovations and keen customer focus, holds global leadership positions in crop protection and non-agricultural pest control. The company also has major activities in seeds and plant traits. Bayer MaterialScience Bayer MaterialScience is a renowned supplier of high-tech polymers and develops innovative solutions for a broad range of applications relevant to everyday life. Products holding leading positions on the world market account for a large proportion of its sales. Left: Bayer researcher Dr. Johannes-Peter Stasch (left) and Professor Hossein Ardeschir Ghofrani from Giessen University Hospital work with a model of a lung. Middle: Vivian Oliver (left) and Gary Henniger from Bayer CropScience examine cotton plants at the new U.S. research center in Lubbock, Texas. Right: Cally Lim (left) inspects wafer-thin solar cells while Wilfredo Aguilar (right) examine luminescent functional films at Bayer’s Singapore facility.
  • Bayer’s Strategy for the Future Bayer’s focus for the future is on innovation and growth in the three areas of health care, nutrition and high-tech materials. Bayer’s business is combined in three subgroups that operate virtually independently and are fully aligned to their respective markets. Each subgroup makes an important contribution to solving the challenges facing society. Bayer HealthCare Bayer HealthCare is among the world’s foremost innovators in the field of pharmaceutical and medical products. This subgroup’s mission is to research, develop, manufacture and market innovative products that improve the health of people and animals throughout the world. Bayer CropScience Bayer CropScience, with its highly effective products, pioneering innovations and keen customer focus, holds global leadership positions in crop protection and non-agricultural pest control. The company also has major activities in seeds and plant traits. Bayer MaterialScience Bayer MaterialScience is a renowned supplier of high-tech polymers and develops innovative solutions for a broad range of applications relevant to everyday life. Products holding leading positions on the world market account for a large proportion of its sales. Left: Bayer researcher Dr. Johannes-Peter Stasch (left) and Professor Hossein Ardeschir Ghofrani from Giessen University Hospital work with a model of a lung. Middle: Vivian Oliver (left) and Gary Henniger from Bayer CropScience examine cotton plants at the new U.S. research center in Lubbock, Texas. Right: Cally Lim (left) inspects wafer-thin solar cells while Wilfredo Aguilar (right) examine luminescent functional films at Bayer’s Singapore facility.
  • Divisions The globally operating HealthCare subgroup is divided into the Pharmaceuticals and Consumer Health segments. The pharmaceuticals includes the following business units: Specialty Medicine: Treatment options for multiple sclerosis, hemophilia and certain types of cancer, among others; contrast media for the precise and early detection of clinical pictures in CT and MR examinations. Women’s Healthcare Hormonal contraception, menopause management and gynecological therapies; &amp; General Medicine: products for high blood pressure, venous thromboembolism, coronary heart diseases, diabetes and infectious diseases, as well as erectile dysfunction and testosterone deficiency in men. Bayer strengthened its pharmaceuticals business through the acquisition of the former Schering AG, Germany, in June 2006 and is as a result among the world’s top ten suppliers of specialty pharmaceuticals. Bayer occupies leading positions in areas such as hormonal contraception (world market leader), contrast agents for diagnostic imaging, as well as multiple sclerosis therapy. Our Consumer Health segment comprises the Consumer Care, Medical Care and Animal Health divisions. The Consumer Care Division has businesses in non-prescription medicines and dietary supplements. Medical Care comprises the businesses with blood glucose meters, contrast-enhanced diagnostic imaging equipment, and mechanical systems for treating constricted or blocked blood vessels. The products of the Animal Health Division are destined for use in food animals and companion animals. Its Animal Health, Consumer Care and Medical Care divisions also occupy leading positions worldwide.
  • Headquarters Bayer is a global enterprise. The management holding company Bayer AG, the operating companies Bayer HealthCare (BHC) and Bayer MaterialScience (BMS), and the service companies Bayer Business Services (BBS), Bayer Technology Services (BTS) and Currenta are all headquartered in Leverkusen, Germany. Bayer CropScience (BCS) is based in nearby Monheim. More information on the company’s locations can be found on the Internet: http://www.bayer.com &gt; Bayer Group &gt; Bayer Worldwide Additional information is available on the Intranet sites of the subgroups and service companies: BHC: http://networld.bhc.cnb/apps/bhc/de/bhc-networld/bhc-networld.nsf/id/EN_Home BCS: http://portal.bayercropscience/bcsweb/PortalCMS.nsf/ID/Home BMS: http://by-networks.bayer-ag.com/intranet/intranet_cms.nsf/id/Home_EN BBS: http://by-bbs.bayer-ag.com/en/ BTS: http://by-bts.bayer-ag.com/en/organization.html Currenta: http://currenta.cnb
  • Bayer HealthCare Headquartered in Leverkusen, Germany, Bayer HealthCare is among the world’s foremost innovators in the field of pharmaceutical and medical products. This subgroup’s mission is to research, develop, manufacture and market innovative products that improve the health of people and animals throughout the world. Bayer HealthCare has roughly 55,700 employees worldwide. Sales in 2010 amounted to EUR 16,913 million. EBITDA before special items reached EUR 4,405 million in 2010. Dr. Jörg Reinhardt is Chairman of the Board of Management of Bayer HealthCare AG and Chairman of the Bayer HealthCare Executive Committee. For further information on Bayer HealthCare, visit: http://networld.bhc.cnb/apps/bhc/de/bhc-networld/bhc-networld.nsf/id/EN_Home
  • Key data full year 2010 by region Europe Adjusted for currency effects, Bayer sales in Europe rose by 5.0 percent to €13,751 million in 2010.   North America Sales on the North American continent reached €8,228 million, a currency-adjusted increase of 0.7 percent. Asia/Pacific Bayer sales in the Asia/Pacific region amounted to €7,481 million, a currency-adjusted increase of 19.3 percent compared to the previous year. Latin America/Africa/Middle East Bayer sales increased by 12.5 percent (currency-adjusted) to €5,628 million in the Latin America/Africa/Middle East region. More information about the regions is available online: http://www.bayer.com/en/Homepage.aspx &gt; Bayer Group &gt; Bayer Worldwide
  • Best-selling Products 2010 (reverse order by sales) Pharma Betaferon ® / Betaseron ® Specialty drug to treat multiple sclerosis YAZ ® / Yasmin ® / Yasminell e ® Hormonal contraceptive Kogenate ® Hemophilia treatment Nexavar ® Drug to treat kidney and liver cancer Adalat ® Hypertension treatment Mirena ® Intrauterine contraceptive Avalox ® / Avelox ® Drug to treat respiratory infections Levitra ® Erectile dysfunction treatment Aspirin Cardio ® Drug product for protection against heart attack Glucobay ® Diabetes treatment Ultravist ® Contrast agent for X-Ray examinations, including CT Cipro ® /Ciprobay ® Medicine to treat infectious diseases Magnevist ® Contrast agent for magnetic resonance imaging Iopamiron ® Non-ionic intravascular contrast agent for all common x-ray analyses Kinzal ® / Pritor ® Drug product for the treatment of hypertension; active ingredient: telmisartan Consumer Health Contour ® Blood glucose measurement device for people with diabetes Aspirin ® Analgesic; active ingredient: acetylsalicylic acid Advantage ® product linie Antiflea product for dogs and cats Aleve ® / Naproxen ® Analgesic; active ingredient: naproxen Bepanthen ® / Bepanthol ® Range of care products to treat dry, irritated skin Canesten ® Antifungal drug for infections of the skin One-A-Day ® Multivitamin product Baytril ® Chemotherapeutic agent for the treatment of severe veterinary infections Supradyn ® Multivitamin and mineral supplement Breeze ® Blood glucose measurement device for people with diabetes Other products Gadovist ® Contrast agent for magnetic resonance imaging of the central nervous system Primovist ® Contrast agent for MRI of the liver Xarelto ® Innovative medicine in tablet form to prevent and treat thrombosis Qlaira ® Oral contraceptive based on estradiol, the estrogen identical to that produced in the female body Baycox ® Drug product to control coccidiosis, a parasitary infectious disease in young livestock Drontal ® product line Dewormers for dogs and cats
  • Employees On December 31, 2010, the Bayer Group had 111,400 employees* worldwide, compared with 111,000 at the end of 2009. Thus headcount remained virtually steady even in the crisis year 2010 (+0.4 %). In Germany we had 36,200 employees (2009: 36,000), who made up 32.5% of the Group workforce. HealthCare employed 55,700 (2009: 55,800) people, CropScience 20,700 (2009: 20,500) and MaterialScience 14,700 (2009: 14,600). The remaining 20,300 (2009: 20,100) employees worked mainly for the service companies. This figure also includes the 700 (2009: 700) employees of Bayer AG. Personnel expenses rose in 2010 by 4.2 % to €8.099 million (2009: €7,776 million), mainly due to exchange-rate effects and the higher contributions to the German pension assurance association. * Employees in full-time equivalents
  • Divisions The globally operating HealthCare subgroup is divided into the Pharmaceuticals and Consumer Health segments. The pharmaceuticals includes the following business units: Specialty Medicine: Treatment options for multiple sclerosis, hemophilia and certain types of cancer, among others; contrast media for the precise and early detection of clinical pictures in CT and MR examinations. Women’s Healthcare Hormonal contraception, menopause management and gynecological therapies; &amp; General Medicine: products for high blood pressure, venous thromboembolism, coronary heart diseases, diabetes and infectious diseases, as well as erectile dysfunction and testosterone deficiency in men. Bayer strengthened its pharmaceuticals business through the acquisition of the former Schering AG, Germany, in June 2006 and is as a result among the world’s top ten suppliers of specialty pharmaceuticals. Bayer occupies leading positions in areas such as hormonal contraception (world market leader), contrast agents for diagnostic imaging, as well as multiple sclerosis therapy. Our Consumer Health segment comprises the Consumer Care, Medical Care and Animal Health divisions. The Consumer Care Division has businesses in non-prescription medicines and dietary supplements. Medical Care comprises the businesses with blood glucose meters, contrast-enhanced diagnostic imaging equipment, and mechanical systems for treating constricted or blocked blood vessels. The products of the Animal Health Division are destined for use in food animals and companion animals. Its Animal Health, Consumer Care and Medical Care divisions also occupy leading positions worldwide.
  • Warum viel versprechende Kandidaten scheitern: Strategische Gründe 44% Ungenügende Wirksamkeit 28% Nebenwirkungen 11% Finanzielle Gründe 9% Sonstige Gründe 8%
  • Divisions The globally operating HealthCare subgroup is divided into the Pharmaceuticals and Consumer Health segments. The pharmaceuticals includes the following business units: Specialty Medicine: Treatment options for multiple sclerosis, hemophilia and certain types of cancer, among others; contrast media for the precise and early detection of clinical pictures in CT and MR examinations. Women’s Healthcare Hormonal contraception, menopause management and gynecological therapies; &amp; General Medicine: products for high blood pressure, venous thromboembolism, coronary heart diseases, diabetes and infectious diseases, as well as erectile dysfunction and testosterone deficiency in men. Bayer strengthened its pharmaceuticals business through the acquisition of the former Schering AG, Germany, in June 2006 and is as a result among the world’s top ten suppliers of specialty pharmaceuticals. Bayer occupies leading positions in areas such as hormonal contraception (world market leader), contrast agents for diagnostic imaging, as well as multiple sclerosis therapy. Our Consumer Health segment comprises the Consumer Care, Medical Care and Animal Health divisions. The Consumer Care Division has businesses in non-prescription medicines and dietary supplements. Medical Care comprises the businesses with blood glucose meters, contrast-enhanced diagnostic imaging equipment, and mechanical systems for treating constricted or blocked blood vessels. The products of the Animal Health Division are destined for use in food animals and companion animals. Its Animal Health, Consumer Care and Medical Care divisions also occupy leading positions worldwide.
  • Best-selling Products 2010 (reverse order by sales) Pharma Betaferon ® / Betaseron ® Specialty drug to treat multiple sclerosis YAZ ® / Yasmin ® / Yasminell e ® Hormonal contraceptive Kogenate ® Hemophilia treatment Nexavar ® Drug to treat kidney and liver cancer Adalat ® Hypertension treatment Mirena ® Intrauterine contraceptive Avalox ® / Avelox ® Drug to treat respiratory infections Levitra ® Erectile dysfunction treatment Aspirin Cardio ® Drug product for protection against heart attack Glucobay ® Diabetes treatment Ultravist ® Contrast agent for X-Ray examinations, including CT Cipro ® /Ciprobay ® Medicine to treat infectious diseases Magnevist ® Contrast agent for magnetic resonance imaging Iopamiron ® Non-ionic intravascular contrast agent for all common x-ray analyses Kinzal ® / Pritor ® Drug product for the treatment of hypertension; active ingredient: telmisartan Consumer Health Contour ® Blood glucose measurement device for people with diabetes Aspirin ® Analgesic; active ingredient: acetylsalicylic acid Advantage ® product linie Antiflea product for dogs and cats Aleve ® / Naproxen ® Analgesic; active ingredient: naproxen Bepanthen ® / Bepanthol ® Range of care products to treat dry, irritated skin Canesten ® Antifungal drug for infections of the skin One-A-Day ® Multivitamin product Baytril ® Chemotherapeutic agent for the treatment of severe veterinary infections Supradyn ® Multivitamin and mineral supplement Breeze ® Blood glucose measurement device for people with diabetes Other products Gadovist ® Contrast agent for magnetic resonance imaging of the central nervous system Primovist ® Contrast agent for MRI of the liver Xarelto ® Innovative medicine in tablet form to prevent and treat thrombosis Qlaira ® Oral contraceptive based on estradiol, the estrogen identical to that produced in the female body Baycox ® Drug product to control coccidiosis, a parasitary infectious disease in young livestock Drontal ® product line Dewormers for dogs and cats
  • Bayer HealthCare – Key Data Full Year 2010 Sales of the HealthCare subgroup rose by 5.8% in 2010 to €16,913 million (2009: €15,988 million). Adjusted for currency and portfolio effects, the increase was 1.7%. The improvement was driven by the positive development of the Consumer Health segment. EBIT of the HealthCare subgroup fell by 29.5% in 2010 to €1,861 million (2009: €2,640 million). Special items totaled minus €1,169 million (2009: minus €372 million). EBIT before special items, at €3,030 million (2009: €3,012 million), was in line with the previous year (+0.6%), while EBITDA before special items declined by 1.4% to €4,405 million (2009: €4,468 million). This was largely attributable to the effects of health system reforms in various countries, the early genericization of YAZ ® in the United States and higher selling expenses in both segments. We also raised our spending on research and development. However, earnings were supported by positive currency effects. Further information about the company’s financials is available in the current version of the Annual Report, which is available online: http://www.annualreport.bayer.com
  • Bayer HealthCare – Key Data Full Year 2010 Sales of the HealthCare subgroup rose by 5.8% in 2010 to €16,913 million (2009: €15,988 million). Adjusted for currency and portfolio effects, the increase was 1.7%. The improvement was driven by the positive development of the Consumer Health segment. EBIT of the HealthCare subgroup fell by 29.5% in 2010 to €1,861 million (2009: €2,640 million). Special items totaled minus €1,169 million (2009: minus €372 million). EBIT before special items, at €3,030 million (2009: €3,012 million), was in line with the previous year (+0.6%), while EBITDA before special items declined by 1.4% to €4,405 million (2009: €4,468 million). This was largely attributable to the effects of health system reforms in various countries, the early genericization of YAZ ® in the United States and higher selling expenses in both segments. We also raised our spending on research and development. However, earnings were supported by positive currency effects. Further information about the company’s financials is available in the current version of the Annual Report, which is available online: http://www.annualreport.bayer.com
  • Bayer HealthCare – Key Data Full Year 2010 Sales of the HealthCare subgroup rose by 5.8% in 2010 to €16,913 million (2009: €15,988 million). Adjusted for currency and portfolio effects, the increase was 1.7%. The improvement was driven by the positive development of the Consumer Health segment. EBIT of the HealthCare subgroup fell by 29.5% in 2010 to €1,861 million (2009: €2,640 million). Special items totaled minus €1,169 million (2009: minus €372 million). EBIT before special items, at €3,030 million (2009: €3,012 million), was in line with the previous year (+0.6%), while EBITDA before special items declined by 1.4% to €4,405 million (2009: €4,468 million). This was largely attributable to the effects of health system reforms in various countries, the early genericization of YAZ ® in the United States and higher selling expenses in both segments. We also raised our spending on research and development. However, earnings were supported by positive currency effects. Further information about the company’s financials is available in the current version of the Annual Report, which is available online: http://www.annualreport.bayer.com
  • Best-selling Products 2010 (reverse order by sales) Pharma Betaferon ® / Betaseron ® Specialty drug to treat multiple sclerosis YAZ ® / Yasmin ® / Yasminell e ® Hormonal contraceptive Kogenate ® Hemophilia treatment Nexavar ® Drug to treat kidney and liver cancer Adalat ® Hypertension treatment Mirena ® Intrauterine contraceptive Avalox ® / Avelox ® Drug to treat respiratory infections Levitra ® Erectile dysfunction treatment Aspirin Cardio ® Drug product for protection against heart attack Glucobay ® Diabetes treatment Ultravist ® Contrast agent for X-Ray examinations, including CT Cipro ® /Ciprobay ® Medicine to treat infectious diseases Magnevist ® Contrast agent for magnetic resonance imaging Iopamiron ® Non-ionic intravascular contrast agent for all common x-ray analyses Kinzal ® / Pritor ® Drug product for the treatment of hypertension; active ingredient: telmisartan Consumer Health Contour ® Blood glucose measurement device for people with diabetes Aspirin ® Analgesic; active ingredient: acetylsalicylic acid Advantage ® product linie Antiflea product for dogs and cats Aleve ® / Naproxen ® Analgesic; active ingredient: naproxen Bepanthen ® / Bepanthol ® Range of care products to treat dry, irritated skin Canesten ® Antifungal drug for infections of the skin One-A-Day ® Multivitamin product Baytril ® Chemotherapeutic agent for the treatment of severe veterinary infections Supradyn ® Multivitamin and mineral supplement Breeze ® Blood glucose measurement device for people with diabetes Other products Gadovist ® Contrast agent for magnetic resonance imaging of the central nervous system Primovist ® Contrast agent for MRI of the liver Xarelto ® Innovative medicine in tablet form to prevent and treat thrombosis Qlaira ® Oral contraceptive based on estradiol, the estrogen identical to that produced in the female body Baycox ® Drug product to control coccidiosis, a parasitary infectious disease in young livestock Drontal ® product line Dewormers for dogs and cats
  • Our Values Bayer’s corporate culture is an important factor in the company’s success. Central to this culture are our values: Leadership, Integrity, Flexibility and Efficiency – or LIFE for short. They provide us with guidance for our daily work as we seek solutions to the major challenges of our time, in line with our mission “ Bayer: Science For A Better Life” . Further information: life.intranet.cnb
  • Left: Medical provision: The aim is to facilitate access to drugs and health services for people all over the world. Middle: Safeguarding nutrition: Food chain partnerships should help secure food supplies in the future. Right: Climate protection: The Bayer CropScience child care center in Monheim, Germany, is an example of an EcoCommercial Building. Our objective is to develop innovative solutions that will help address global challenges such as providing sustainable health care, feeding a steadily growing world population, combating climate change and overcoming the scarcity of natural resources. We therefore plan to align our core businesses to sustainability criteria even more rigorously than before. In 2009 we launched the Bayer Sustainability Program. Major areas of focus are our alliances for sustainable health care, innovative partnerships to improve the supply of high-quality food, and new solutions for protecting the climate and managing natural resources. More information: http://www.bayer.com/en/sustainable-development-program-smik.aspx
  • Sustainable Development and Corporate Social Responsibility We are committed to the principles of sustainable development , and to our role as a socially and ethically responsible corporate citizen . For us, there is a clear link between technical and economic expertise and corporate social responsibility. This, in turn, we define as our responsibility to work for the benefit of humankind, become socially involved and make a lasting contribution to sustainable development. At Bayer, we regard economy, ecology and social commitment as objectives of equal rank. As part of its commitment to corporate citizenship, Bayer supports a wide range of projects worldwide in the fields of education and research, environment and nature, basic social needs, sports and the arts. Carl Duisberg established the first Bayer foundation for medical students in 1923. In the decades that followed, a broadly based foundation culture developed under the Bayer name that concentrated on supporting education and science on the one hand and disabled athletes on the other. Bayer has pooled and expanded its traditional foundation activities with the establishment of two new organizations in 2007: the “Bayer Science &amp; Education Foundation” and the “Bayer Cares Foundation.” The Bayer Science &amp; Education Foundation mainly aims to support talented schoolchildren, ambitious students and outstanding scientists. Personal commitment and specialist excellence are regarded as central criteria for selection. Activities that qualify for support could include such endeavors as school programs at our production sites, innovative projects initiated by students and scientific symposia. Bayer makes available an additional foundation budget of EUR 10 million for school projects. The Bayer Cares Foundation aims to help improve living conditions at our sites and solve central social problems. A key role here is played by the sponsoring of voluntary commitment in the local communities surrounding our sites. The Bayer Cares Foundation also provides donations to quickly help those placed in a position of need following natural disasters, for example. Our Making Science Make Sense program (MSMS) was initiated more than ten years ago to encourage interest in the natural sciences among U.S. school students. More than 1,200 Bayer employees now support scientific education in these countries by regularly volunteering their time to help teach at elementary schools. In 2006, Bayer was awarded the Ron Brown Award for Corporate Leadership by the U.S. President for this initiative, the first non-U.S. company to receive this prize. In the meantime, this educational initiative has been extended to Bayer sites in Brazil, Colombia, Denmark, France, India, Ireland, Italy, Japan, Singapore, Taiwan and the United Kingdom. For further information and additional projects supported by Bayer: http://www.bayer.com/en/Sustainability-and-Commitment.aspx http://www.sustainability.bayer.com
  • The Bayer Sustainability Strategy It is the overriding goal of Bayer’s sustainability strategy to allow the company to be guided by long-term values. We want to balance successful, sustainable development with social needs and goals. Bayer is committed to sustainable development. We want to meet this commitment on three levels: 1. Through our products and innovations, which are the heart of our business. These are designed to benefit people and improve their quality of life. 2. Through our business activities, i.e. how we run our business. We want to act responsibly across the entire value-added chain – toward all our stakeholders, especially our employees, customers, suppliers and stockholders. 3. Through our social commitment: our foundations and voluntary social activities. We also want to meet our responsibility to society by becoming socially involved as a good corporate citizen. As part of society, we are influenced by social trends, needs and goals, as are our markets. To become more familiar with these and incorporate them into our business strategies, we are involved in a close exchange with our stakeholders. For further information: http://www.bayer.com/en/Sustainability-and-Commitment.aspx http://www.sustainability.bayer.com http://www.bayer.com/en/sustainable-development-program-smik.aspx
  • Transcript of "Bayer HealthCare Overview"

    1. 1. Bayer HealthCare Overview March 2011
    2. 2. Content Overview Group Structures Pharma Research & Development Consumer Health Financial Data People and Responsibility
    3. 3. Full year sales: € 16.9 billion 55,700 employees R&D expenditures: € 2.1 billion As of December 31, 2010
    4. 4. Group Structure Currenta Bayer Business Services Bayer HealthCare Bayer MaterialScience Bayer CropScience Business areas Service areas Holding company Corporate Center Bayer Technology Services Bayer AG Group Management Board
    5. 5. Business Areas High-tech materials Health care Nutrition MaterialScience HealthCare CropScience
    6. 6. Bayer HealthCare Divisions Animal Health Medical Care Consumer Care Pharmaceuticals Pharma Consumer Health
    7. 7. Bayer HealthCare Divisions Consumer Care <ul><li>Non-prescription drugs </li></ul><ul><li>Vitamins </li></ul>Pharmaceuticals <ul><li>General Medicine </li></ul><ul><ul><li>Women’s Healthcare </li></ul></ul><ul><li>Specialty Medicine </li></ul><ul><ul><li>Diagnostic Imaging </li></ul></ul>Animal Health <ul><li>Food Animal Products </li></ul><ul><li>Companion Animals </li></ul>Medical Care <ul><li>Diabetes Care: blood glucose monitoring systems and accessories </li></ul><ul><li>Medrad: medical devices and services that enable imaging and therapeutic procedures </li></ul>
    8. 8. Bayer HealthCare Divisional Headquarters Europe Africa / Middle East North America Asia / Pacific Latin America Medical Care Tarrytown, NY, USA Consumer Care Morristown, NJ, USA Animal Health Monheim, Germany Pharmaceuticals Berlin, Germany Bayer HealthCare Leverkusen, Germany
    9. 9. Bayer HealthCare Full Year 2010 Employees* 55,700 Sales € 16,913 million EBITDA before special items € 4,405 million Chairman of the Executive Committee Dr. Jörg Reinhardt * Employees in full-time equivalents
    10. 10. Global Leader in Specialty Pharmaceuticals and Consumer Health Animal Health Division 64.5% 6.6% 19.9% € 16,913 million BHC Sales 2010 Employees 2010: 55,700 Consumer Care Division Medical Care Division 9.0% Consumer Health Pharmaceuticals Pharmaceuticals Division € 1,120 million € 3,371 million € 1,514 million € 10,908 million
    11. 11. Bayer HealthCare Aspirations <ul><li>Be one of the world’s leading diversified healthcare companies </li></ul><ul><li>Strengthen Pharma with focus on specialties </li></ul><ul><li>Build a world-class consumer health business </li></ul><ul><li>Aspire for leading position and above-market growth in each market segment </li></ul><ul><li>Expand business in emerging markets </li></ul>
    12. 12. Employees in 2010 R&D 7,700 Bayer HealthCare 55,700 Employees in full-time equivalents Pharmaceuticals 38,000 Consumer Health 17,700
    13. 13. Bayer HealthCare Pharmaceuticals
    14. 14. Bayer HealthCare Pharmaceuticals Key Data <ul><li>Biggest pharma company in Germany </li></ul><ul><li>focus on 2 major business units: General Medicine, Specialty Medicine </li></ul><ul><li>Employees 2010: 38,000 (2009: 38,000) </li></ul><ul><li>Investment in R&D: mid-term 15% of total net sales </li></ul>10,467 10,908 Sales in € million <ul><li>General Medicine </li></ul><ul><ul><li>Women’s Healthcare </li></ul></ul><ul><li>Specialty Medicine </li></ul><ul><ul><li>Diagnostic Imaging </li></ul></ul>Pharmaceuticals
    15. 15. Bayer HealthCare Pharmaceuticals Women’s Healthcare <ul><ul><li>We are the world’s leading company in the field of hormonal contraception </li></ul></ul><ul><ul><li>Product range: </li></ul></ul><ul><ul><ul><li>Both oral and non-oral contraceptives </li></ul></ul></ul><ul><ul><ul><li>Products for menopause management as well as gynecological therapies </li></ul></ul></ul><ul><ul><li>Our research activities include therapies for gynecological diseases such as endometriosis and uterine fibroids </li></ul></ul>
    16. 16. Bayer HealthCare Pharmaceuticals General Medicine <ul><ul><li>We are strong partners in the areas of infectious diseases and anti-infective therapy for pulmonology, cardiology and thrombosis, and urology </li></ul></ul><ul><ul><li>Product range: </li></ul></ul><ul><ul><ul><li>Preparations to treat hypertension, coronary heart disease and diabetes </li></ul></ul></ul><ul><ul><ul><li>Antibiotics to fight respiratory, urinary and surgical infections </li></ul></ul></ul><ul><ul><ul><li>Treatments for testosterone deficiency and erectile dysfunction in men </li></ul></ul></ul><ul><ul><ul><li>Preparations for the prevention of venous thromboembolism </li></ul></ul></ul><ul><ul><li>We are pursuing clinical research for the treatment of pulmonary and cardiovascular diseases </li></ul></ul>
    17. 17. Bayer HealthCare Pharmaceuticals Specialty Medicine <ul><ul><li>We are among the world’s leading companies in the fight against severe chronic and life-threatening diseases such as multiple sclerosis (MS), hemophilia and certain types of cancer </li></ul></ul><ul><ul><li>Product range: </li></ul></ul><ul><ul><ul><li>Products for treating multiple sclerosis (MS) </li></ul></ul></ul><ul><ul><ul><li>Products for the treatment of the bleeding disorder hemophilia A </li></ul></ul></ul><ul><ul><ul><li>Cancer therapies to combat solid tumors </li></ul></ul></ul><ul><ul><li>Maximizing the value of strong specialty pipeline by internal R&D capabilities and partnerships to sustain long-term growth </li></ul></ul>
    18. 18. Bayer HealthCare Pharmaceuticals Diagnostic Imaging <ul><ul><li>We are the global leader in contrast media </li></ul></ul><ul><ul><li>Product range: </li></ul></ul><ul><ul><ul><li>Contrast media for classic X-ray procedures and computer tomography (CT) </li></ul></ul></ul><ul><ul><ul><li>Contrast media for magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) </li></ul></ul></ul><ul><ul><li>We are pursuing clinical research of innovative approaches in the field of molecular imaging, e.g. possibilities of diagnosing Alzheimer's disease </li></ul></ul>
    19. 19. Research & Development
    20. 20. Probability of success from research to market approval: <1% Drug research Preclinical Clinical trials Evaluation/ Approval Phase IV studies Source: based on PhRMA Profile Pharmaceutical Industry 2010 Years 0 2 4 6 8 10 12 14 16 18 (up to 2 years) (more than 2 years) 10,000 Test compounds <250 Test compounds <5 Test compounds Lab and animal experiments 1 drug ap- proved by health authorities € >2 billion Phase I: 20-100 healthy volunteers Phase II: 100-500 patients  safety, dosing Phase III: 1,000-10,000 patients  efficacy, adverse events
    21. 21. Bayer HealthCare Pharmaceuticals Research Areas <ul><li>Pulmonary hypertension / heart failure </li></ul><ul><li>Thrombosis / acute coronary syndrome </li></ul><ul><li>Hematology / LCM Kogenate </li></ul><ul><li>CNS Imaging </li></ul><ul><li>Oncology Imaging </li></ul><ul><li>Cardiovascular Imaging </li></ul><ul><li>Anti-angiogenesis </li></ul><ul><li>Cell cycle control / apoptosis </li></ul><ul><li>Transcription and chromatin modulation </li></ul>Cardiology / Hematology Women’s Healthcare Diagnostic Imaging Oncology “ Common Mechanism Research” <ul><li>Endometriosis </li></ul><ul><li>Uterine Fibroids </li></ul><ul><li>LCM Contraception / Menopause Management </li></ul>
    22. 22. Bayer HealthCare Pharmaceuticals Research at a Glance Berkeley / San Francisco <ul><li>Hematology </li></ul><ul><li>Biologics Research </li></ul><ul><li>U.S. Innovation Center Mission Bay </li></ul>Berlin <ul><li>Oncology </li></ul><ul><li>Women’s Healthcare </li></ul><ul><li>Diagnostic Imaging </li></ul>Wuppertal / Cologne <ul><li>Cardiology </li></ul><ul><li>Oncology </li></ul>Beijing <ul><li>GDD Innovation Center China </li></ul><ul><li>Bayer Tsinghua Center for Innovative Drug Discovery </li></ul><ul><li>Investment in R&D 2010: € 1.8 billion </li></ul><ul><li>Investment in R&D of 2010 total net sales: 16.1% </li></ul><ul><li>R&D Employees: 6,200 (2010) </li></ul>
    23. 23. Our R&D Pipeline Provides a Balanced Mix of NME and LCM Opportunities New Molecular Entities (NME) Life Cycle Management (LCM) Status as of March 2011 Selection of major Pharmaceuticals pipeline projects Cancer CA9-ADC Cancer PI3K Inhibitor Cancer CDK-Inhibitor Anemia HIF-PH CHF MR Antagonist Diagnostic Imaging PET-Tracer Sympt. Uterine Fibroids S-PRAnt MCI Florbetaben Hemophilia BAY 94-9027 Hemophilia Rec. Factor VIIa Medical ill Xarelto VTE Treatment Xarelto ACS Xarelto wet AMD VEGF Trap-Eye CRVO VEGF Trap-Eye Myopic CNV VEGF Trap-Eye PAH Riociguat (sGC Stimulator) CTEPH Riociguat (sGC Stimulator) CRC Regorafenib GIST Regorafenib Bone Mets HRPC Alpharadin Alzheimer PET Imaging Florbetaben Submental fat removal ATX-101 Breast Cancer Nexavar Ovarian / Peritoneal Cancer Nexavar CRC Nexavar Additional Indications Nexavar Lung Infection Cipro inhale Gram-negative Pneumonia Amikacin inhale NSCLC Nexavar Thyroid Cancer Nexavar Breast Cancer Nexavar Multiple Sclerosis Alemtuzumab Contraception LCS (ULD LNG) Contraception FC Patch Low MRI LCM Gadovist VV Atrophy / FSD Vaginorm Phase I (10) Phase II (15) Phase III (21) DME VEGF Trap-Eye PH-COPD Riociguat (sGC Stimulator) PH-ILD Riociguat (sGC Stimulator) PH-LHD Riociguat (sGC Stimulator) Cancer Regorafenib Cancer MEK-Inhibitor Bone Mets Breast Cancer Alpharadin Atopic Dermatitis Mapracorat (SEGRA) ED BAY 60-4552/Vardenafil
    24. 24. Improving R&D Efficiency and Maximizing the Value of Transformational Late-Stage Pharmaceutical Pipeline Assets <ul><li>Establish Xarelto ® (rivaroxaban) as an ideal anticoagulant with the potential to redefine the market </li></ul><ul><li>Demonstrate Nexavar ® ’s potential as a pan-tumor drug and a building block of Bayer’s global oncology franchise </li></ul><ul><li>Create a new standard of care in multiple sclerosis with alemtuzumab </li></ul><ul><li>Transform hemophilia market by developing a long-acting Kogenate ® </li></ul><ul><li>Establish a new paradigm in the treatment of age-related macular degeneration with VEGF Trap-Eye </li></ul>
    25. 25. Consumer Health
    26. 26. Consumer Health Key Data Sales in € million 977 1,120 Animal Health <ul><li>Food Animal Products </li></ul><ul><li>Companion Animals </li></ul><ul><li>Business activities in more than 120 countries </li></ul>Consumer Care <ul><li>Non-prescription drugs </li></ul><ul><li>Vitamins </li></ul><ul><li>Business activities in more than 100 countries </li></ul>Medical Care <ul><li>Diabetes Care: blood glucose monitoring systems and accessories </li></ul><ul><li>Medrad: medical devices and services that enable imaging and therapeutic procedures </li></ul><ul><li>Business activities in more than 100 countries </li></ul>3,080 3,371 1,464 1,514
    27. 27. Leading Growth in Consumer Health at Bayer HealthCare Animal Health <ul><li>Continue growth at or above market at high profitability </li></ul><ul><li>Growth from major brands as well as in emerging markets </li></ul><ul><li>Provide increased funding for innovation </li></ul><ul><li>Continue implementation of new Innovation Approach to bring more innovative products to market faster </li></ul>Consumer Care <ul><li>Capitalize on consistently outperforming market growth </li></ul><ul><li>Growth through building strong brands </li></ul><ul><li>Growth through innovation </li></ul><ul><li>Rx-to-OTC switch opportunities </li></ul><ul><li>Expansion into high growth markets </li></ul>Medical Care <ul><li>Develop and commercialize customer-relevant innovations </li></ul><ul><li>Reduce gap to leaders and expand into new/adjacent segments in developed markets </li></ul><ul><li>Invest strategically and establish sustainable positions in emerging markets </li></ul>
    28. 28. Consumer Health Top 10 Products 2009 2010 Contour ® (Medical Care) 601 602 Aspirin ® * (Consumer Care) 400 418 Advantage ® product line (Animal Health) 336 408 Aleve ® / naproxen (Consumer Care) 217 273 Bepanthen ® / Bepanthol ® (Consumer Care) 186 212 Canesten ® (Consumer Care) 188 210 One A Day ® (Consumer Care) 153 178 Baytril ® (Animal Health) 149 166 Supradyn ® (Consumer Care) 136 138 Breeze ® (Medical Care) 138 125 * total Aspirin ® sales = EUR 776 million (2009: EUR 715 million), including Aspirin Cardio ® , which is reflected in sales of the Pharmaceuticals segment Product [sales in € million ]
    29. 29. Consumer Health Animal Health <ul><ul><li>Animal Health is a top player with benchmark profitability which supplies solutions for domestic animals and farm animals </li></ul></ul><ul><ul><li>Product and development portfolio includes a nti-infectives and treatments against p arasiticides </li></ul></ul><ul><ul><li>Growth through development of innovative products, successful life cycle management and licensing and acquisitions </li></ul></ul>
    30. 30. Consumer Health Consumer Care <ul><ul><li>Consumer Care is a top-tier OTC (over the counter) player </li></ul></ul><ul><ul><li>Product portfolio includes analgesics, nutritionals, dermatological products, gastrointestinal and cardiovascular therapeutics as well as drugs for cough & cold </li></ul></ul><ul><ul><li>Well positioned for future growth faster than market and to outpace competition </li></ul></ul>Aleve ® / naproxen, Antra ® , Aspirin ® , Bepanthen ® / Bepanthol ® , One A Day ® , Rennie ® , Supradyn ® Product selection:
    31. 31. Consumer Health Medical Care <ul><ul><li>With Diabetes Care, Medical Care is one of the world’s market leaders in the field of blood glucose monitoring systems </li></ul></ul><ul><ul><li>Product portfolio includes devices and test strips for blood glucose monitoring </li></ul></ul><ul><ul><li>We are committed to leading in diabetes management and monitoring on a global basis </li></ul></ul><ul><ul><li>Medrad develops, markets and services diagnostic imaging and therapeutic medical devices used to diagnose and treat cardiovascular and other diseases. Product portfolio includes vascular injection systems and thrombectomy devices </li></ul></ul>Diabetes Care: Breeze ® , Contour ® MEDRAD: Stellant ® , MEDRAD Avanta ® , AngioJet ® Product selection:
    32. 32. Financial Data
    33. 33. Key Data 2010 Bayer HealthCare Sales Pharmaceuticals Consumer Health EBITDA Special items EBITDA before special items EBITDA margin before special items EBIT Special items EBIT before special items Gross cash flow Net cash flow [ € million ] 16,913 10,908 6,005 4,116 (289) 4,405 26.0% 1,861 (1,169) 3,030 2,948 3,320 15,988 10,467 5,521 4,148 (320) 4,468 27.9% 2,640 (372) 3,012 3,153 3,431 2009 2010 +5.8% +4.2% +8.8% -0.8% -1.4% -29.5% +0.6% -6.5% -3.2% Change
    34. 34. Key Data 2010 Pharmaceuticals 2009 2010 Sales Women’s Healthcare and General Medicine Specialty Medicine EBITDA Special items EBITDA before special items EBITDA margin before special items EBIT Special items EBIT before special items Gross cash flow Net cash flow 2009 figures restated +4.2% +4.3% +4.0% -2.7% -2.9% -47.9% +0.3% -9.3% -0.4% 10,908 6,816 4,092 2,834 (266) 3,100 28.4% 884 (1,140) 2,024 1,983 2,272 10,467 6,532 3,935 2,912 (281) 3,193 30.5% 1,696 (322) 2,018 2,186 2,280 [ € million ] Change
    35. 35. Key Data 2010 Consumer Health 2009 2010 Sales Consumer Care Medical Care Animal Health EBITDA Special items EBITDA before special items EBITDA margin before special items EBIT Special items EBIT before special items Gross cash flow Net cash flow +8.8% +9.4% +3.4% +14.6% +3.7% +2.4% +3.5% +1.2% -0.2% -8.9% 6,005 3,371 1,514 1,120 1,282 (23) 1,305 21.7% 977 (29) 1,006 965 1,048 5,521 3,080 1,464 977 1,236 (39) 1,275 23.1% 944 (50) 994 967 1,151 [ € million ] Change
    36. 36. People and Responsibility
    37. 37. Our Vision Science For A Better Life As an innovative healthcare company, we will: <ul><li>Shape the future with innovations that will benefit the health and well-being of people and animals </li></ul><ul><li>Lead the industry in our chosen therapeutic areas and will direct our research and development to therapeutic areas where there is a high unmet medical need </li></ul><ul><li>Be respected for our high-performance culture and for attracting, retaining and developing the best talents </li></ul><ul><li>Be trusted by our customers </li></ul><ul><li>Deliver on our promises to stakeholders </li></ul><ul><li>Act in a socially responsible manner </li></ul>
    38. 38. Our Values <ul><li>Leadership </li></ul><ul><li>Be passionate for people and performance </li></ul><ul><li>Show personal drive, inspire and motivate others </li></ul><ul><li>Be accountable for actions and results, successes and failures </li></ul><ul><li>Treat others fairly and with respect </li></ul><ul><li>Give clear, candid and timely feedback </li></ul><ul><li>Manage conflicts constructively </li></ul><ul><li>Create value for all our stakeholders </li></ul><ul><li>Integrity </li></ul><ul><li>Be a role model </li></ul><ul><li>Comply with laws, regulations and good business practices </li></ul><ul><li>Trust others and build trustful relationships </li></ul><ul><li>Be honest and reliable </li></ul><ul><li>Listen attentively and communicate appropriately </li></ul><ul><li>Ensure sustainability: balance short-term results with long-term requirements </li></ul><ul><li>Care about people, safety and the environment </li></ul><ul><li>Flexibility </li></ul><ul><li>Drive change actively </li></ul><ul><li>Be ready to adapt to future trends and needs </li></ul><ul><li>Challenge the status quo </li></ul><ul><li>Think and act with customers in mind </li></ul><ul><li>Seek out opportunities and take calculated risks </li></ul><ul><li>Be open-minded </li></ul><ul><li>Embrace lifelong learning </li></ul><ul><li>Efficiency </li></ul><ul><li>Manage resources smartly </li></ul><ul><li>Focus on activities that create value </li></ul><ul><li>Do things simply and effectively </li></ul><ul><li>Deliver with appropriate costs, speed and quality </li></ul><ul><li>Speed up good decision-making </li></ul><ul><li>Be accountable for consistent execution </li></ul><ul><li>Collaborate for better solutions </li></ul>
    39. 39. Responsible Action in Society As a research-based pharmaceutical company, we support projects aimed at reducing the differences in medical care standards for people all over the world. Among others, Bayer HealthCare is committed to the following initiatives: Social healthcare programs <ul><li>Access to medicines in developing countries </li></ul><ul><li>Family planning programs </li></ul>WHO cooperation: Provision of medicines free of charge <ul><li>Fight against Chagas disease </li></ul><ul><li>Fight against African sleeping sickness </li></ul>Fight against tuberculosis <ul><li>Development of a new treatment option in cooperation with The Global Alliance for TB Drug Development </li></ul>
    40. 40. Sustainable Development and Corporate Social Responsibility Foundations: <ul><li>Bayer Science & Education Foundation: Support for talented schoolchildren, ambitious students and outstanding scientists </li></ul><ul><li>Bayer Cares Foundation: Help to improve living conditions at our sites by supporting social projects </li></ul><ul><li>Commitment to the principles of sustainable development and our role as a socially and ethically responsible corporate citizen </li></ul><ul><li>Economy, ecology and social commitment are objectives of equal rank </li></ul><ul><li>Social activities in the fields of education and research, environment and nature, basic social needs, sports and the arts </li></ul>
    41. 41. The Bayer Sustainability Concept Goal: Successful and sustainable business in harmony with social objectives and needs Corporate Social Responsibility Products & Innovations Business Activities Stakeholder Society
    42. 42. Thank you!
    43. 44. Forward-Looking Statements <ul><li>This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. </li></ul><ul><li>Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. </li></ul><ul><li>The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. </li></ul>

    ×